In a recent interview with Tracy Weslosky, Dr. Carolyn Myers, President, CEO, and Director of FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF), shared insights into the progress and strategic initiatives surrounding their groundbreaking REPELWRAP™ film, a film that significantly reduces adhesion of bacteria and viruses on surfaces. Collaborating with Dunmore International Corp., their manufacturing partner, FendX has achieved pivotal advancements in automating and refining the production process of REPELWRAP™ film, targeting efficiency enhancements such as reduced changeovers and optimized heating and drying phases. These improvements are key to streamlining production and ensuring the product is cost-effective without sacrificing performance.

Dr. Myers emphasized the critical next steps involving rigorous real-world testing to confirm the film’s durability and efficacy against bacteria and viruses in varied environments, including healthcare and other high traffic venues. Such testing, previously conducted in McMaster University’s lab, demonstrated the film’s promising potential. FendX aims to transition to commercial production by the year’s end, with aspirations to begin revenue generation in the first half of 2025.

The partnership with McMaster University, which facilitated the exclusive licensing of the nanotechnology IP for REPELWRAP™ film, was highlighted as instrumental in meeting developmental milestones. The strategic relationship with Dunmore was also underscored as vital for advancing the product towards commercialization. Dr. Myers exemplifies a commitment to delivering innovative solutions designed to mitigate pathogen transmission on surfaces, marking a significant leap towards enhancing public health safety.

To access the complete interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., click here

Disclaimer: FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the “Company”), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on www.sedarplus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

As we approach the highly anticipated InvestorTalk tomorrow morning, I am delighted to be preparing for an InvestorTalk that promises to be both enlightening and engaging. With Dr. Carolyn Myers at the helm from 9-9:20 AM EST, we are set to do a coffee talk Q&A style, as we secure the latest advancements and strategic directions in the realm of nanotechnology and surface protection coatings from the undeniably talented FendX management team. Dr. Myers, CEO of FendX Technologies Inc., is renowned for her visionary leadership and her pivotal role in steering the company towards groundbreaking innovations….check out her LinkedIn profile, and then — here are tomorrow’s details:

9-920 AM EST
Tuesday, February 27, 2024
InvestorTalk with Dr Carolyn Myers from FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF)
Join Zoom Meeting – Click Here

One of the most noteworthy achievements that we will be highlighting during the talk is FendX’s successful completion of its third pilot run for manufacturing REPELWRAP™ film using Dunmore International Corp.’s commercial equipment. This milestone, announced on February 13, 2024, marks a significant leap forward in the company’s quest to optimize the production process of this innovative film.

The journey of REPELWRAP™ film from concept to near-commercialization is a testament to FendX’s relentless pursuit of excellence. The initial pilot run, revealed on October 3, 2023, confirmed the feasibility of scaling up the REPELWRAP™ film formulation for automated manufacturing. This was followed by a second pilot run on January 10, 2024, which introduced a more efficient one-pass coating process, significantly reducing manufacturing time and advancing the scale-up development initiatives.

The third and latest pilot run focused on utilizing the one-pass coating process to further reduce drying times after the nano-coating is applied to the film. This achievement not only enhances the efficiency of the manufacturing process but also supports FendX’s ongoing efforts to refine and perfect their production techniques. With each pilot run, FendX has moved closer to realizing a final commercial manufacturing process, demonstrating significant progress in optimizing the intermediate scale-up of REPELWRAP™ film.

REPELWRAP™ film is poised to revolutionize the way we approach surface protection. Leveraging FendX’s award-winning nanotechnology, this protective coating film exhibits unique properties that prevent the adhesion of pathogens, bacteria, and viruses, thereby reducing their transmission on surfaces prone to contamination. Such innovative solutions are crucial in healthcare settings and various industries, offering a new layer of protection in our fight against the spread of infectious diseases.

Dr. Myers’ leadership has been instrumental in forging strong collaborations with Dunmore and McMaster University, propelling FendX towards its goals with unmatched expertise and dedication. As we prepare to share these exciting developments with our investors and stakeholders, we look forward to a session filled with insightful discussions, strategic foresights, and a glimpse into the future of surface protection technologies.

Tomorrow’s InvestorTalk is not just a presentation of achievements; it’s a celebration of the strides FendX is making towards safer, more protected environments. Join us as we explore the cutting-edge innovations that FendX is bringing to the forefront, under the adept guidance of Dr. Carolyn Myers.

As of the latest financial disclosure, FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF) has 53.04 million common shares outstanding.

In a recent interview with InvestorNews host Tracy Weslosky, FendX Technologies Inc.’s (CSE: FNDX | OTCQB: FDXTF) President, CEO, and Director Dr. Carolyn Myers discussed their recently announced agreement with Dunmore International for a second pilot run of FendX’s REPELWRAP™ film. REPELWRAP™ is an award-winning protective surface coating film that prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination.

This collaboration follows a successful first pilot run where FendX’s REPELWRAP™ film was validated for automated commercial production. Dr. Myers elaborated that the second pilot run is poised to refine formulation processes, paving the way for commercial production anticipated early next year.

Beyond the REPELWRAP™ film, FendX is actively engaged in diversified projects such as spray nanotechnology and coated catheters, underscoring their commitment to make people’s lives safer. With a Master Services Agreement signed with nanoComposix for scale-up development of FendX’s spray nanotechnology, Dr. Myers discussed how coating medical catheters with FendX’s nanotechnology can prevent bacterial biofilm formation and blockage.

To access the complete interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., click here

Disclaimer: FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the “Company”), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on www.sedarplus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In a recent InvestorNews interview with host Tracy Weslosky, Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director, Greg Fenton, discussed China’s recent move to restrict graphite exports and its potential impact on global supply chains and the electric vehicle (EV) industry.

Concerns about China’s dominance in supplying critical minerals to the EV industry have prompted governments to identify this as a significant risk. Greg said that the recent restrictions on graphite exports highlight the importance of creating a North American battery supply chain. Greg underscored the potential for this situation to significantly alter the EV landscape. Foreseeing long-term growth, Greg discussed why electric vehicle manufacturers will need to diversify their supply chains away from China.

Greg believes these restrictions will shift the focus to North American graphite producers. Highlighting Zentek’s Albany graphite deposit in Ontario, Canada, as a promising source of high-purity graphite, Greg emphasized the need for government and industry investments in North American graphite projects.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets.

To learn more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

In a recent interview with Investor.News host Tracy Weslosky, FendX Technologies Inc.’s (CSE: FNDX | OTCQB: FDXTF) President, CEO, and Director Dr. Carolyn Myers delves into two pioneering product streams that underscore FendX’s commitment to infectious disease control.

The REPELWRAP™ surface coating film acts as a powerful shield that repels pathogens such as bacteria and viruses, significantly reducing transmission. Dr. Myers discusses how this nanotechnology holds significant promise for high-traffic industries such as healthcare, schools, and transportation. Further, FendX is developing a spray nanotechnology, which promises even more convenient applications. With the potential to expand into various sectors, this spray-based innovation presents a wider market potential.

Discussing FendX’s formidable and exceptionally well-qualified management team, Dr. Myers emphasized FendX’s strategic vision for expansion through mergers and acquisitions (M&A). Drawing from her wealth of experience, she stressed the pivotal role of M&A in scaling the company’s impact. As FendX focuses on both internal product development and external growth opportunities, the FendX umbrella of infectious disease control reveals a broad landscape of applications waiting to be explored. To access the complete interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., click here

Disclaimer: FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the “Company”), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on www.sedarplus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

How often do you find yourself with subtle post pandemic habits, like pushing doors open with your elbow or forearm, or perhaps you pull your jacket sleeve down over your hand to pull open a door handle? Basically, you are trying to avoid public touch points that have the potential to carry some sort of germs or bugs or other nasties that you’d rather not have on your hands. Things can be even worse in places like hospitals where viruses are an ordinary part of daily life and you can potentially cross paths with some really nasty, antibiotic resistant pathogens. But before I scare you into being afraid to leave the house, have faith that help is on the way.

That help is coming from a company called FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF), a Canadian-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens.

REPELWRAP™ film is the Company’s first product under development and is a protective surface coating film that leverages the Company’s award-winning nanotechnology. REPELWRAP™ film has demonstrated unique repelling properties that prevent the adhesion of pathogens, bacteria, and viruses, reducing their transmission on surfaces prone to contamination. This technology works by combining hierarchical wrinkled molecular structure with chemical functionalization to reduce pathogen adhesion and biofilm formation. When a contaminated hand touches the surface of REPELWRAP™ film, the contamination stays on the contaminated hand and does not transfer to the surface, so no more need for using elbows or sleeves.

FendX believes this technology will be important to control the spread of pathogens on surfaces that are prone to contamination. Research and development results, as published in several journals to date, have shown the original prototype of the film and the early-stage spray formulation to be effective in repelling and preventing biofilm formation of World Health Organization-designated priority pathogens such as Gram-positive methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative Pseudomonas and Enterococci strains, as well as being effective in repelling SARS-CoV-2 related viruses. The product is flexible and can be applied to most surface shapes.  The Company believes REPELWRAP™ film will have applications in healthcare settings and several other industries such as transportation, schools, and sporting facilities.

On the road to commercialization of REPELWRAP™, FendX Technologies Inc. recently announced it had successfully completed the initial development phase with Dunmore International Corp., a global manufacturer of engineered coated and laminated films and foils. As part of the agreement, Dunmore successfully adapted FendX’s lab prototype formulation for making REPELWRAP™ film to its manufacturing production processes. Tests confirmed that the films produced by Dunmore exhibited similar repelling properties to the original lab prototype, leading to the next phase of development, where Dunmore will conduct small production runs on their commercial manufacturing line to create intermediate-sized films for further testing. Automating the manufacturing process for REPELWRAP™ film is a crucial step towards its eventual commercialization.

Along with REPELWRAP™, FendX is developing a spray formulation, licensed on May 16, 2023, which has demonstrated both repelling and pathogen-killing properties. The bifunctional coating uses wrinkled polydimethylsiloxane microparticles decorated with biocidal gold nanoparticles to achieve these effects. Lab testing showed significant reductions in pathogen adhesion and transfer on coated surfaces compared to uncoated ones, with a 99.98% reduction in colony forming units of MRSA and Pseudomonas aeruginosa on nano-coated surfaces. Development work began in June 2023 to assess and advance the formulation for initial scale-up testing and creating intermediate prototypes for further evaluation.

The Company expects to launch REPELWRAP™ film in the Canadian market in the first half of 2024. Management believes that the Company’s current level of cash will be sufficient to execute its current planned expenditures for the next 12 months without the need for further financing. This suggests that if everything goes according to plan, there’s an outside chance FendX could be starting to see revenue before they need to raise capital again. Whether that occurs or not, it’s a safe bet that this time next year investors will have a very good picture of what the potential for this Company could be.

FendX Technologies trades at a market cap of C$13.4 million.

One day in the future there could be special nanomaterials used in hospitals, operating theaters, and medical clinics that act to repel pathogens (viruses, bacteria, etc). The applications for pathogen repelling materials are almost endless. Think of surgical equipment, catheters, and perhaps even our personal gadgets.

A kind of supermaterial coating that can keep the germs away. Well, that future is potentially not so far away! A Canadian company has developed a nanotechnology that repels germs (pathogens).

The Company is FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF) (“FendX”).

FendX’s vision is to contribute to controlling the spread of infectious diseases. Along with their partners, FendX has developed a nanotechnology that repels pathogens. The nanotechnology has unique repelling properties that prevent adhesion of bacteria, viruses, and liquids.

FendX state:

“The repelling properties of our nano-surfaces prevents adhesion of bacteria and viruses. We believe our technology will have numerous applications and opportunities in healthcare and other industries.”

And:

“Our nanotechnology causes both high surface tension (e.g., water) and low surface tension (e.g., oil) liquids to form droplets when they come in contact with the nano-surface.“

FendX is developing both film and spray products to protect surfaces from contamination

Source: FendX technologies website

REPELWRAP™ film

FendX’s lead product under development is known as REPELWRAP™ film. It works by repelling pathogens. REPELWRAP™ is being developed in conjunction with FendX’s partners at McMaster University. FendX has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

FendX states:

“The Company has a growing intellectual property portfolio consisting of licensed nonprovisional national stage patent applications which have been made in Canada, the United States, Europe, China, Hong Kong and Japan, as well as two licensed PCT applications. Our licensed nanotechnology has been featured in CNN Health, Materials Today, and Engineering.com.“

REPELWRAP™ film won the grand prize of the “2020 Create the Future Design” contest, beating out approximately 750 entries from 60 countries around the world.

As announced in June 2023 FendX is progressing the manufacturing stage for REPELWRAP™ film through their agreement with Dunmore International Corp. (“Dunmore”). The initial setup and testing of the manufactured product has been completed. The next stage of development involves conducting small runs on Dumore’s commercial manufacturing line to create intermediate sized films for further testing.

Dr. Carolyn Myers, CEO of FendX stated:

“We are very pleased Dunmore has successfully replicated the REPELWRAP™ film lab prototype in their R&D lab and that they can now begin to automate the manufacturing process…..This achievement marks a significant step forward in our scale-up initiatives as FendX has met an important REPELWRAP™ film development milestone.“

Spray coating

On July 20, 2023, FendX announced that they had signed a collaborative research agreement with McMaster University for the development of the ‘Spray Coating Formulation’.

The Spray Coating can be easier to quickly apply to high-touch surfaces. This is an exciting recent step forward for FendX as it expands the potential product marketplace.

Closing remarks

FendX is moving forward at warp speed. Product development and small scale commercial manufacturing of REPELWRAP™ film is already underway. A spray coating with similar applications is also starting to be developed.

You can learn more about FendX by reading the June 2023 Letter to Shareholders.

FendX Technologies trades on a market cap of C$15 million. It looks like a huge potential opportunity for FendX if they can market and sell their products well in future years. I would expect hospitals and surgeries would be very interested to buy some FendX REPELWRAP™ film or spray once it is available. Stay tuned.

In this InvestorIntel interview, Tracy Weslosky talks with NEO Battery Materials Ltd.’s (TSXV: NBM | OTCQB: NBMFF) Strategy and Operations Manager Danny Huh about their ongoing commercialization and optimization process to achieve the 1000-Mile Electrical Vehicle Battery using silicon anode materials.

Having achieved a significant technology milestone of uniform nanocoating capability on silicon anodes, Danny explains how their technology can help increase the driving range of electric vehicles and enable ultra-fast charging.

The company is constructing a commercial plant in South Korea to expedite the commercialization process and aims to provide silicon anodes for battery manufacturers and EV automakers.

With a “top-notch R&D team”, NEO Battery Materials is currently constructing a plant in South Korea to expedite the commercialization process and aims to provide silicon anodes for battery manufacturers and EV automakers.

Danny provides an update on NEO Battery Materials’ expansion in the United States and also discusses how NEO Battery Materials plans to capitalize on the emergence of Ontario, Canada as a strategic battery hub with the battery gigafactories being built in the region.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About NEO Battery Materials Ltd.

NEO Battery Materials Ltd. is a Vancouver-based company focused on electric vehicle lithium-ion battery materials. NEO has a focus on producing silicon anode materials through its proprietary single-step nanocoating process, which provides improvements in capacity and efficiency over lithium-ion batteries using graphite in their anode materials. The Company intends to become a silicon anode active materials supplier to the electric vehicle industry.

To learn more about NEO Battery Materials Ltd., click here

Disclaimer: NEO Battery Materials Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this PDAC 2023 InvestorIntel interview Tracy Weslosky speaks with David Stevenson, Founder and CEO of Lithium ONE Environmental Inc. (L1X Corp.), which has a fully commercialized Nano extraction technology for the separation and production of battery-grade lithium from brine with zero external water consumption.

David tells Tracy about its plans for three pilot projects in Mexico, Chile, and Argentina for L1X Lithium™, its clean and sustainable lithium mining solution that requires no evaporation ponds and no pollution for an efficient and a complete path for lithium separation and production from brine for battery-grade output.

To access the full InvestorIntel interview, click here.

Subscribe to the InvestorIntel YouTube channel by clicking here.

About Lithium ONE Environmental Inc.

Lithium ONE Environmental Inc. (L1X Corp) is proud to be the first lithium mining company able to produce and deliver Clean Sourced Lithium™. Our approach to mining is via joint venture or PPP (public-private-partnership). We have removed the investment-technology risk.  Together, we can meet the rising global demand for clean-sourced lithium. 

To learn more about Lithium ONE Environmental Inc., click here.

Disclaimer: This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

In this InvestorIntel interview during PDAC 2023, Tracy Weslosky talks to Sixth Wave Innovations Inc.’s (CSE: SIXW | OTCQB: SIXWF) CEO, President, and Director, Dr. Jon Gluckman about how Sixth Wave’s lithium extraction technology offers “phenomenal ESG improvements for hard rock lithium mining.” In addition to recently simplifying its process flow sheet and significantly lowering energy usage, Dr. Gluckman discusses how their technology uses safer and greener reagents to produce battery-grade lithium carbonate.

Providing an update on Sixth Wave’s IXOS® gold extraction technology, Dr. Gluckman discusses how their technology offers a superior replacement for activated carbon used in the gold mining industry. Speaking about the success achieved with their gold extraction technology, Dr. Gluckman explains how their technology can help gold mines reduce their all-in-sustaining-cost (AISC) by as much as US$100-200 per ounce.

Sixth Wave is in negotiations with multiple lithium properties and several gold mines to use its processing technology as well as moving ahead with several projects in non-mining sectors as well.

To access the full InvestorIntel interview, click here.

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Sixth Wave Innovations Inc.

Sixth Wave is a nanotechnology company with patented technologies that focus on the extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its IXOS^® – AuC polymer for the gold mining industry is focused on expanding the offerings as noted here in lithium. The Company’s patent portfolio covers extensions of the designs for extraction and purification of other critical metals including nickel, cobalt, rare earth elements, and platinum group metals.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company has successfully developed nanotechnology architectures that are highly relevant for the detection and separation of viruses, bacteria, biogenic amines, and other pathogens. The Company is finishing commercialization of its Affinity™ system for purification of cannabinoids. The Company is actively looking for licensing opportunities to monetize these assets as it focuses on the mining and critical metals industry.

To learn more about Sixth Wave Innovations Inc., click here

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].